CClinicalTrials.gg
TerminatedNCT05381116REDUCEOABUpdated May 29, 2024

A Sham-Controlled Study to Evaluate the Safety and Efficacy of a Smart, Self-Adjusting, Surgery-Free, Wearable Bladder Neuromodulation System for Overactive Bladder

An interventional study of Avation System and Sham Avation System in Overactive Bladder, Urinary Urge Incontinence and Urge Incontinence, sponsored by Avation Medical, Inc.. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-29.

Sponsored by Avation Medical, Inc. · Not applicable, Interventional, and Treatment

Why this study was terminated
Sponsor Initiated

From the registry’s dates

  • Primary completion was Jul 2023, 3 years 3 months ago, and no results have been posted to the registry.
Phase
Not applicable
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a prospective, multi-center, sham-controlled study comparing the safety and effectiveness of the self-adjusting, surgery-free, wearable Active System to a Sham System on adult Subjects diagnosed with OAB.

02

Conditions studied

  • Overactive Bladder
  • Urinary Urge Incontinence
  • Urge Incontinence

Keywords

  • Overactive Bladder
  • OAB
  • Urinary Incontinence
  • Neuromodulation
  • Bioelectronic Medicine
  • Urologic Disorders
  • Wearable
  • Digital Health
  • Closed-Loop
  • EMG
  • Sham
  • Continuous Sensing
  • Automatic Adjustment
03

In context

Urinary Bladder, Overactive

855 studies on the registry are indexed under Urinary Bladder, Overactive; 125 are open to participants now.

This study's enrollment of 125 is above the median of 72 across 652 interventional studies indexed under Urinary Bladder, Overactive.

Browse Urinary Bladder, Overactive studies →

Lead sponsor

Avation Medical, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Male or female and 18 years of age or older at the time of enrollment
  2. Willing and capable of giving informed consent
  3. Willing and able to comply with all Study-related requirements and procedures
  4. Have been diagnosed or have symptoms of OAB for at least 3 months prior to enrollment
  5. Have an average of 11 or more voiding events and/or 3 or more incontinent events per 24-hour period in a 3-Day Bladder Diary(a minimum of 30 voiding events over the 3 days measured by the Diary)
  6. If currently on medications that may affect their OAB symptoms, is on a stable dose (no new, discontinued, or change in dose) of all prescribed medications for at least 4 weeks prior to enrollment or throughout the Study
  7. Female Subjects of child-bearing potential must have a negative urine dip stick pregnancy test at baseline

Exclusion criteria

Exclusion Criteria:

  1. Has been diagnosed with incontinence due to neurogenic bladder(stroke, CNS tumors, Parkinson's etc.)
  2. Have failed a third line treatment (PTNS, Botox or SNS) for their OAB because of lack of effectiveness within the 2 years prior to enrollment
  3. Have evidence of an uncontrolled active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance of intervention and/or ability to evaluate treatment outcomes, in the opinion of the Investigator
  4. Has or had a significant untreated substance use disorder or polysubstance use disorder stemming from dependency-producing medications, alcohol, and/or illicit drugs less than 6 months prior to enrollment
  5. Are planning to or have scheduled a surgery, for any condition, that would require catheterization, or a prolonged hospital stay and affect the ability to ambulate, use the toilet, or complete Therapy during the first 12 weeks of the Study
  6. Has symptoms of, been diagnosed, or being actively treated for benign prostatic hyperplasia or prostate cancer (weak stream, straining, hesitancy, or intermittency)
  7. Have a pacemaker or implanted defibrillator
  8. Has a neurological disorder that affects the bladder or a diagnosis of interstitial cystitis, radiation cystitis, or fistulas
  9. Incontinence due to stress-predominant mixed urinary incontinence (greater that 60% of the time)or being actively treated for stress urinary incontinence(Diagnosed or by review of the Baseline 3-Day Bladder Diary)
  10. Has been diagnosed with or has symptoms of polyuria (>2500 cc urine output per day)
  11. Has urinary retention or incomplete bladder emptying
  12. Have a documented current or reoccurring Urinary Tract Infection (3 or more in the months prior to enrollment)
  13. Have had Botox treatment for their OAB in the previous 8 months
  14. Have used TENS anywhere on the body within the last year for any reason or anticipated use of TENS within 12 weeks of enrollment in pelvic region, back or legs for any reason
  15. Had PTNS treatment for OAB within 6 months prior to enrollment.
  16. Use of investigational drug/device Therapy, for any reason, within past 12 weeks
  17. Current use or implantation of an implanted device for treatment of their OAB or incontinence (including but not limited to sacral nerve stimulators)
  18. Participation in another clinical Study during the term of the Study
  19. Pregnant or planning to become pregnant during the Study. Female Subjects of childbearing potential who become pregnant during the Study will be withdrawn from the Study and will be asked to sign a separate pregnancy consent form to allow the Investigator and Sponsor to follow up on the Subject's pregnancy and outcome
  20. Has scar tissue, metal, or another implant or a large tattoo that might interfere with Therapy
  21. Has a neurological disorder that causes abnormal sensations in the lower leg (loss of sensation or allodynia)
  22. Has a skin condition, for example allergic reaction, rash or open wounds, in the area of where the Therapy Garment will be placed
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
125 participants (actual)

Study arms

  • Active comparator
    Experimental Arm

    Avation System

    Device: Avation System

  • Sham comparator
    Control Arm

    Sham Avation System

    Device: Sham Avation System

Interventions

  • DeviceAvation System

    Subjects will perform therapy with active Avation System three (3) times a week for thirty (30) minutes each time over a 12-week period. At the end of the twelve (12) weeks of therapy, eligible Subjects from the Active Arm will be offered the opportunity to participate in the additional twenty one (21) month Open-Label Phase.

  • DeviceSham Avation System

    Subjects will perform therapy with sham Avation System three (3) times a week for thirty (30) minutes each time over a 12-week period. At the end of the twelve (12) weeks of therapy, all Subjects from the Sham Arm will be offered the opportunity to crossover and participate in the additional twenty one (21) month Open-Label Phase.

06

What researchers measure

Primary outcomes

  1. The proportion of Subjects with a successful response

    The proportion of Subjects with a successful response, where success is defined as: For enrolled Subjects that meet the inclusion criteria for average voids per day (frequency): a Subject that achieves a 50% or greater reduction, from baseline (Visit 1) to Week 12 (Visit 4), in average voids per day relative to an upper normal limit of an average of 8 voids per day, or For enrolled Subjects that meet the inclusion criteria for incontinence events per day: a Subject that achieves a 50% or greater reduction from baseline (Visit 1) to Week 12 (Visit 4) in average incontinence events (IE) per day.

    Time frame: Blinded Lead-In Portion of Study,12 Weeks

Secondary outcomes

  1. Quality of Life Endpoints: Questionnaires

    Evaluation of the Subject Quality of Life questionnaires used throughout the duration of the trial.

    Time frame: Length of Study, 24 months

Other outcomes

  1. Open-Label Phase Endpoints

    During the Open-Label Phase, efficacy endpoints for enrolled Subjects that meet the inclusion criteria for average voids per day (frequency): a Subject that achieves a 50% or greater reduction, from baseline (Visit 1) in average voids per day relative to an upper normal limit of an average of 8 voids per day, or for enrolled Subjects that meet the inclusion criteria for incontinence events per day: a Subject that achieves a 50% or greater reduction from baseline (Visit 1) to in average incontinence events (IE) per day, except that Subjects initially enrolled in the Sham Arm will convert to Active Therapy (3x per week for 12 weeks followed by at least 1x per week for the remainder of the Study) and endpoints will be measured against their baseline (Visit 1) diary. .

    Time frame: Length of Study, 24 months

07

Study locations

6 sites
  • Eclipse Clinical Research
    Tucson, Arizona 85745, United States
  • Women's Health Institute
    Oak Lawn, Illinois 60453, United States
  • Ochsner Medical Center
    New Orleans, Louisiana 70121, United States
  • Regional Urology
    Shreveport, Louisiana 71106, United States
  • Flourish Research
    San Antonio, Texas 78229, United States
  • Tranquil Medical Rsearch
    Webster, Texas 77598, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05381116
Lead sponsor
Avation Medical, Inc.
Responsible party
Sponsor
First posted
May 19, 2022
Start date
Apr 14, 2022
Primary completion
Jul 1, 2023
Completion
Jul 1, 2023
Last update
May 29, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion